• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

5 months ago
R&D
FDA+

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

5 months ago
Deals

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

5 months ago
Startups
R&D

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

5 months ago
Pharma
FDA+

Ag­i­lent re­veals plans to re­mod­el op­er­a­tions as an­nu­al rev­enue dips

5 months ago
Manufacturing

Avice­da aims to raise $200M; Ner­viano gets back rights to PARP1 in­hibitor

5 months ago
News Briefing

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

5 months ago
R&D

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

5 months ago
Deals
Cell/Gene Tx

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

5 months ago
R&D

Cra­dle Bio rais­es $73M Se­ries B to sell phar­ma its pro­tein-mak­ing AI soft­ware

5 months ago
Deals
AI

Why Mor­gan Health is back­ing an autism care com­pa­ny

5 months ago
Financing
Health Tech

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

5 months ago
R&D

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

5 months ago
R&D

Bris­tol My­ers re­veals more job cuts in New Jer­sey

5 months ago
Pharma

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

5 months ago
FDA+

Min­neso­ta 340B rev­enue dri­ven by hos­pi­tals and high-priced drugs, first state re­port says

5 months ago
Pharma

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

5 months ago
Pharma

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

5 months ago
R&D

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

5 months ago
R&D

Bio­haven's myo­statin in­hibitor miss­es pri­ma­ry end­point in spinal mus­cu­lar at­ro­phy tri­al

5 months ago
R&D

Replimune aims to raise $125M; Ot­su­ka makes an­oth­er deal with Io­n­is

5 months ago
News Briefing

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

5 months ago
Startups
Deals

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

5 months ago
Financing
Startups

As­traZeneca’s Truqap edges clos­er to prostate can­cer la­bel ex­pan­sion with Phase 3 win

5 months ago
R&D
Pharma
First page Previous page 60616263646566 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.